Adding folic acid (vitamin B9) to daily treatment of enalapril reduced the risk of first stroke in Chinese adults with hypertension, especially among those with low platelet count (PLT) and high total homocysteine (tHcy), according to post hoc analysis of the CSPPT*.
Non-vitamin K antagonist oral anticoagulants (NOACs) offer better efficacy and safety, especially in terms of risk of stroke and major bleeding, respectively than warfarin for Asian patients with atrial fibrillation (AF), according to a presentation at APSC Congress 2018. The benefits were also greater for Asians compared with non-Asians.
Whether the 2017 ACC/AHA* blood pressure (BP) guidelines should be adopted in Asian countries was the topic of a much-anticipated discussion here at the Asian Pacific Society of Cardiology (APSC) Congress 2018 in Taiwan last week.
In children and adolescents with cystic fibrosis (CF), synbiotic supplementation appears to be effective at reducing proinflammatory markers such as interleukin (IL)-6 and -8, and nitric oxide metabolites (NOx), a recent study has found.
Use of oxaliplatin-containing adjuvant chemotherapy (ACT) may prolong survival in locally advanced rectal cancer patients who have shown pathological complete response after preoperative chemoradiotherapy, according to a study.
Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor is superior to ezetimibe in reducing low-density lipoprotein cholesterol (LDL-C), with or without statin therapy, according to a study presented at the Asian Pacific Society of Cardiology Congress 2018 (APSC 2018) in Taipei, Taiwan. Additionally, PCSK9 inhibitor shows comparable safety profile.
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.
Basal insulin peglispro (BIL) provided superior glucose-lowering efficacy over insulin glargine (GL) in insulin-naïve Asian patients with type 2 diabetes (T2D) that is inadequately controlled by oral antihyperglycaemic medications (OAMs), a phase III study has shown.
Use of nitazoxanide appears to be safe and effective in the treatment of patients with hepatic encephalopathy, producing substantial reductions in the Clinical Hepatic Encephalopathy Staging Scale score and improvements in mental status, according to a study.
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.